Table 5.
Performance of models in predicting PHLF in subgroups based on tumor stage.
| Models | BCLC-0 and A stage | BCLC-B and C stage | ||
|---|---|---|---|---|
| AUC | 95%CI | AUC | 95%CI | |
| Child–Pugh score | 0.593 | 0.448–0.738 | 0.583 | 0.409–0.757 |
| MELD score | 0.629 | 0.485–0.773 | 0.745 | 0.656–0.834 |
| ALBI score | 0.754 | 0.645–0.863 | 0.707 | 0.546–0.867 |
| FIB-4 index | 0.774 | 0.663–0.885 | 0.726 | 0.599–0.853 |
| ALBI-FIB4 | 0.802 | 0.695–0.909 | 0.766 | 0.613–0.919 |
ALBI albumin-bilirubin, BCLC barcelona clinic liver cancer, FIB-4 fibrosis-4, MELD model for end-stage liver disease, PHLF post-hepatectomy liver failure.